Paris, January 29, 2013 - Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities and GenoSplice Technology, developers of bioinformatics solutions for analysis of genomic data, today announce that they have formed a partnership to combine their expertise.
This collaboration will provide GenoSplice with access to several Curie-Cancer technology platforms to allow it to continue to improve its services to its clients. GenoSplice will, in turn, be included in Institut Curie research programs and will benefit from access to the intellectual property generated during the projects. This agreement will allow GenoSplice to specifically contribute to the development of new products against cancer. The agreement also facilitates better understanding of complex diseases such as cancer through genome mapping.
Curie-Cancer, in developing Institut Curie’s industry partnership activities, chose to collaborate with GenoSplice, a specialized bioinformatics solutions provider with very high value-added genomic data analysis. GenoSplice will use Curie-Cancer’s genomic platform to continue to offer data processing to their primary client base - large pharmaceutical laboratories, biotechnology companies and academic research centers. The clients use GenoSplice to process the data gathered from high-speed sequencing and/or DNA microarrays, as well as to obtain a better understanding of the biological mechanisms involved with alternative splicing for their R&D projects.
One specific project in the collaboration will consist of defining a genomic map for prostate cancer. The map will be based on the analysis of data obtained from several hundred patients suffering from this type of cancer. The goal is twofold: to better understand the mechanisms involved in this disease and to group patients in order to guide clinicians in selecting therapeutic options.
A second project regards a new therapeutic approach in cancer treatment that will use a new type of “cell penetrating peptide” molecule. The effectiveness of one of these molecules has already been demonstrated in mice on xenograft models representative of human tumors. The purpose of the project will be to identify the predictive markers of response to this molecule in order to select the patients who are most likely to respond positively to this new treatment. GenoSplice contributes with expertise enabling the identification of these markers, which will then allow treatments to be administered to patients most effectively.
“Combining the skills and expertise of GenoSplice and Curie-Cancer will allow us to provide cutting-edge bioinformatics solutions that are very competitive in the field of genomics,” said Marc Rajaud, president and co-founder, GenoSplice.
“Participating in research projects with the Institut Curie, which are sometimes multi-party and involve other international research institutes, will put us at the forefront of developments in our areas of interest and will enable us to provide the best possible service to our clients,” said Pierre de la Grange, scientific director and co-founder, GenoSplice.
“In addition to the prospect of being able to provide an additional therapeutic solution for our patients, we are pleased to be able to contribute to the development of a French SME, while progressing towards a greater understanding of cancers,” says Damien Salauze, director of Curie-Cancer. “Once again it’s clear that the expertise and experimental models developed at the Institut Curie for the purposes of fundamental research also meet the needs expressed by our partners in the industry. The Carnot label we obtained in 2011 is a testament to this.”
Curie-Cancer is the body responsible for developing Institut Curie’s industry partnership activities. It oversees the institute’s existing industry partnerships as well as areas of high potential interest to industry partners. Institut Curie’s 1,200 researchers provide the high level of expertise in oncology required to collaborate with industry partners in creating and subsequently developing cancer therapies.
Curie-Cancer management has extensive industry experience and can call upon a vast pool of scientists involved in basic and clinical research. In 2011, Curie-Cancer was awarded the “Institut Carnot” label by the French government, which recognizes excellence and involvement in research partnerships.
About Institut Curie
Institut Curie is a private foundation founded in 1909 by Marie Curie, the first woman Nobel prize-winner and the first Nobel prize-double winner. It is the leading comprehensive cancer center (combining research and patient care) in Europe. Institut Curie’s research center and hospital employ some 3,200 scientists, physicians, nurses, technicians and administrative staff. The institute’s current objectives include increasing the proportion of research programs carried out in partnership with industry so that research results can lead to faster availability of products and services for the benefit of patients.
For more information, go to: http://www.curie.fr/en
GenoSplice, with its unique expertise in bioinformatics, is a leader in the analysis of expression data. It develops and markets high value-added services internationally in the analysis of genomic data gathered through high-speed sequencing and/or DNA microarrays. The company uses proprietary tools to provide its innovative services and maintains long-term collaborative relationships. Each client is unique, just as each analysis process is unique.
GenoSplice’s services primarily concern data analysis: gene expression, alternative splicing, microRNA, fusion transcripts, epigenetics, SNP, CNV, translocation and proteomics.
ANDREW LLOYD & ASSOCIATES
Follow us on Twitter: https://twitter.com/ALA_Group
Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND
Tel: +44 1273 675100
Fax: +44 1273 675400
55 rue Boissonade 75014 Paris FRANCE
Tel: +33 1 56 54 07 00
Fax: +33 1 56 54 07 01
INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION